ABCL Stock Overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AbCellera Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.86 |
| 52 Week High | US$8.05 |
| 52 Week Low | US$3.58 |
| Beta | 0.42 |
| 1 Month Change | -3.74% |
| 3 Month Change | -20.41% |
| 1 Year Change | -45.01% |
| 3 Year Change | -86.46% |
| 5 Year Change | n/a |
| Change since IPO | -93.45% |
Recent News & Updates
Recent updates
AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
Dec 05AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
Oct 18AbCellera Biologics: I Was Wrong
Aug 20AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be
Aug 17AbCellera Biologics: A Buy At Current Prices
Aug 06AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff
May 31Shareholder Returns
| ABCL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 4.3% | -0.1% | 1.2% |
| 1Y | -45.0% | 8.0% | 27.7% |
Return vs Industry: ABCL underperformed the US Life Sciences industry which returned 8% over the past year.
Return vs Market: ABCL underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ABCL's share price has been volatile over the past 3 months.
Volatility Over Time: ABCL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 586 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
AbCellera Biologics Inc. Fundamentals Summary
| ABCL fundamental statistics | |
|---|---|
| Market cap | US$1.13b |
| Earnings (TTM) | -US$146.90m |
| Revenue (TTM) | US$35.79m |
31.7x
P/S Ratio-7.7x
P/E RatioIs ABCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABCL income statement (TTM) | |
|---|---|
| Revenue | US$35.79m |
| Cost of Revenue | US$31.78m |
| Gross Profit | US$4.01m |
| Other Expenses | US$150.90m |
| Earnings | -US$146.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 11.19% |
| Net Profit Margin | -410.48% |
| Debt/Equity Ratio | 0% |
How did ABCL perform over the long term?
See historical performance and comparison